Literature DB >> 15181068

The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort.

Richard A Kronmal1, Joshua I Barzilay, Russell P Tracy, Peter J Savage, Trevor J Orchard, Gregory L Burke.   

Abstract

It is not known whether insulin levels, in the setting of insulin treatment, are an independent risk factor for coronary heart disease (CHD). We studied a cohort of 116 insulin-treated individuals, 65 yr or older, who were followed for 5.6-9 yr. All were free of CHD at baseline. There were 47 incident CHD events. In Cox proportional hazards modeling, with fasting immune-reactive insulin levels as a continuous variable, the hazard ratio for CHD was statistically significant (P < 0.0001). When insulin levels were divided into intervals, those in the third interval [43-150 microU/ml (258-900 pmol/liter)] had an adjusted 30% increased relative risk (95% confidence interval, 0.57, 2.98) compared with those in the first interval [<20 microU/ml (<120 pmol/liter)]. Those in the fourth interval [151-400 microU/ml (906-2400 pmol/liter)] had an adjusted 5.6-fold increased risk (2.3-13.1; P < 0.0001). Approximately 15% of the cohort had such elevated insulin levels. Immune-reactive insulin levels were strongly correlated with specific insulin, proinsulin, and insulin antibody levels. Markedly elevated fasting immune-reactive insulin levels were an independent risk factor for CHD in this study of insulin-treated older adults. These observational findings should be confirmed through larger prospective studies, given their implications for insulin therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181068     DOI: 10.1210/jc.2003-031822

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Effect of serum insulin on the association between hyperuricemia and incident heart failure.

Authors:  Ravi V Desai; Mustafa I Ahmed; Gregg C Fonarow; Gerasimos S Filippatos; Michel White; Inmaculada B Aban; Wilbert S Aronow; Ali Ahmed
Journal:  Am J Cardiol       Date:  2010-10-15       Impact factor: 2.778

Review 2.  Effects of chronic hyperinsulinemia in insulin-resistant patients.

Authors:  Sergio Muntoni; Sandro Muntoni; Boris Draznin
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

3.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

Review 4.  Diabetic cardiovascular disease: getting to the heart of the matter.

Authors:  Linda R Peterson; Clark R McKenzie; Jean E Schaffer
Journal:  J Cardiovasc Transl Res       Date:  2012-05-26       Impact factor: 4.132

5.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

6.  Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies.

Authors:  Pengcheng Xun; Ying Wu; Qianchuan He; Ka He
Journal:  Am J Clin Nutr       Date:  2013-10-16       Impact factor: 7.045

7.  The association between C-reactive protein levels and insulin therapy in obese vs nonobese veterans with type 2 diabetes mellitus.

Authors:  Sameed Ahmed M Khatana; Tracey H Taveira; Andrea G Dooley; Wen-Chih Wu
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-06       Impact factor: 3.738

8.  Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors.

Authors:  Carlo B Giorda; Angelo Avogaro; Marina Maggini; Flavia Lombardo; Edoardo Mannucci; Salvatore Turco; Stefania Spila Alegiani; Roberto Raschetti; Mario Velussi; Ele Ferrannini
Journal:  Diabetes Care       Date:  2008-09-09       Impact factor: 17.152

9.  Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog.

Authors:  Dale S Edgerton; Mary C Moore; Jason J Winnick; Melanie Scott; Ben Farmer; Helle Naver; Claus B Jeppesen; Peter Madsen; Thomas B Kjeldsen; Erica Nishimura; Christian L Brand; Alan D Cherrington
Journal:  Diabetes       Date:  2014-06-19       Impact factor: 9.461

10.  Carotid body denervation prevents the development of insulin resistance and hypertension induced by hypercaloric diets.

Authors:  Maria J Ribeiro; Joana F Sacramento; Constancio Gonzalez; Maria P Guarino; Emília C Monteiro; Sílvia V Conde
Journal:  Diabetes       Date:  2013-03-25       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.